Nijhuis M - Search Results

1

Comparison of digital PCR platforms and semi-nested qPCR as a tool to determine the size of the HIV reservoir.

Bosman KJ, Nijhuis M, van Ham PM, Wensing AM, Vervisch K, Vandekerckhove L, De Spiegelaere W. Bosman KJ, et al. Among authors: nijhuis m. Sci Rep. 2015 Sep 9;5:13811. doi: 10.1038/srep13811. Sci Rep. 2015. PMID: 26350506 Free PMC article.

2

A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants.

van Maarseveen NM, Huigen MC, de Jong D, Smits AM, Boucher CA, Nijhuis M. van Maarseveen NM, et al. Among authors: nijhuis m. J Virol Methods. 2006 May;133(2):185-94. doi: 10.1016/j.jviromet.2005.11.008. Epub 2005 Dec 20. J Virol Methods. 2006. PMID: 16368153

3

Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.

van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M. van Maarseveen NM, et al. Among authors: nijhuis m. J Infect Dis. 2007 Feb 1;195(3):399-409. doi: 10.1086/510533. Epub 2006 Dec 29. J Infect Dis. 2007. PMID: 17205479

4

Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.

Huigen MC, van Ham PM, de Graaf L, Kagan RM, Boucher CA, Nijhuis M. Huigen MC, et al. Among authors: nijhuis m. Retrovirology. 2008 Feb 13;5:20. doi: 10.1186/1742-4690-5-20. Retrovirology. 2008. PMID: 18271957 Free PMC article.

5

Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

Nijhuis M, Wensing AM, Bierman WF, de Jong D, Kagan R, Fun A, Jaspers CA, Schurink KA, van Agtmael MA, Boucher CA. Nijhuis M, et al. J Infect Dis. 2009 Sep 1;200(5):698-709. doi: 10.1086/605329. J Infect Dis. 2009. PMID: 19627247

6

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

Wensing AM, van Maarseveen NM, Nijhuis M. Wensing AM, et al. Among authors: nijhuis m. Antiviral Res. 2010 Jan;85(1):59-74. doi: 10.1016/j.antiviral.2009.10.003. Epub 2009 Oct 22. Antiviral Res. 2010. PMID: 19853627 Review.

7

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.

Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M. Verheyen J, et al. Among authors: nijhuis m. AIDS. 2010 Mar 13;24(5):669-73. doi: 10.1097/QAD.0b013e32833160fa. AIDS. 2010. PMID: 19926962

8

Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.

van Lelyveld SF, Nijhuis M, Baatz F, Wilting I, van den Bergh WM, Kurowski M, de Jong D, Hoepelman AI, Wensing AM. van Lelyveld SF, et al. Among authors: nijhuis m. Clin Infect Dis. 2010 Feb 1;50(3):387-90. doi: 10.1086/649874. Clin Infect Dis. 2010. PMID: 20047481

9

Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.

Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M. Fun A, et al. Among authors: nijhuis m. J Antimicrob Chemother. 2010 Nov;65(11):2300-4. doi: 10.1093/jac/dkq319. Epub 2010 Aug 24. J Antimicrob Chemother. 2010. PMID: 20736234

10

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.

Symons J, van Lelyveld SF, Hoepelman AI, van Ham PM, de Jong D, Wensing AM, Nijhuis M. Symons J, et al. Among authors: nijhuis m. J Antimicrob Chemother. 2011 Apr;66(4):890-5. doi: 10.1093/jac/dkq535. Epub 2011 Jan 28. J Antimicrob Chemother. 2011. PMID: 21393136

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters